Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Implandata Ophthalmic Products GmbH

https://www.implandata.com/

Latest From Implandata Ophthalmic Products GmbH

Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Deals Business Strategies

OUS Approvals Analysis: IVDs Lead A Slow Month

Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.

Approvals Innovation

Glaucoma: Devices Go Eye-to-Eye With Drugs

This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.

In Glaucoma, Devices Go Eye-to-Eye with Drugs

Glaucoma is of serious interest to VCs and strategic investors because of its sheer size; the disease affects 3 million people, most of them managed by drugs. Glaucoma drugs have created a $4 billion market, but have several problems, the greatest of which is non-compliance. Glaukos and other device companies aim to introduce devices that are safe and efficacious enough to compete directly with drugs, rather than standing in as an alternative to today's glaucoma surgeries reserved for end-stage patients. Glaukos recently marked a first of its kind victory; with a tiny implantable ophthalmic stent, Glaukos emerged from a PMA clinical trial that convinced an FDA panel of the benefit-to-risk ratio of its approach when used as a first-line therapy in a select group.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
UsernamePublicRestriction

Register